在基石投资者方面，英矽智能引入包括礼来公司、腾讯、淡马锡、施罗德、瑞银、橡树资本、易方达、 泰康人寿等在内的15家全球化基石投资者，涵盖全球制药龙头、互联网巨头、国际主权基金与大型资管 机构以及国内头部公募与险资。其中，礼来公司与腾讯首次认购生物医药企业基石投资，显示跨界产业 头部公司对AI制药赛道的认可；美国长线投资机构橡树资本年内首次以基石投资者身份重回港股 Biotech市场，彰显其对香港资本市场及创新医药长期价值的持续看好。 英矽智能创始人兼首席执行官、首席商务官Alex Zhavoronkov表示："此次超额认购的上市创下多项全 球纪录，进一步彰显了英矽智能在人工智能驱动药物研发领域经实践验证的领先地位，以及市场对我们 AI平台和产品管线的认可。" 12月30日，由生成式人工智能驱动的临床阶段生物医药科技公司英矽智能(股份代码：03696.HK)在港交 所上市，成为首家通过联交所主板上市规则8.05条上市的AI生物医药科技公司。该股开盘价为35港元， 较发行价上涨45.53%。 英矽智能本次IPO募集资金总额22.77亿港元，是年内募集资金最高的港股Biotech(生物科技公司)IPO。 据悉，英矽 ...

Market Overview - The Hong Kong stock market indices collectively rose, with the Hang Seng Index increasing by 0.44% to 25,749.19 points, the Hang Seng Tech Index up by 1.04%, and the National Enterprises Index rising by 0.67% [12][16] - Technology stocks saw significant gains, with Baidu rising over 6% and both NetEase and JD.com increasing by over 1% [12][16] Semiconductor Sector - The semiconductor sector showed strong performance, highlighted by InnoCare Technologies' stock rising over 9% [3][14] - According to Galaxy Securities, the semiconductor industry is experiencing a structural market driven by price increases in the supply chain, sustained AI demand, and strengthened domestic substitution logic [3][14] - The long-term trend emphasizes supply chain security and self-sufficiency, particularly in upstream equipment and materials under the domestic substitution framework [3][14] Oil Sector - The oil sector also performed well, with CNOOC's stock increasing by over 4% [4][12] - CNOOC reported that the Hainan offshore oil and gas field group is expected to exceed 10 million tons of oil equivalent production by 2025, marking five consecutive years of production growth and setting a new record for the field group [4][6] - The "Deep Sea No. 1" Phase II project has been fully operational this year, significantly boosting the overall production capacity of the field group [4][6] New Listings - Six new stocks were listed today, with notable performances including InnoCare Technologies rising over 34%, Meilian Shares increasing by over 30%, and Wuyi Vision up by over 18% [12][16] - Other new listings included Lin Qingxuan, which rose by over 14%, while Woan Robotics remained flat and Xun Ce saw a slight decline [12][16]

12月30日，英矽智能正式在港交所主板挂牌上市，成为港股"AI制药第一股"。 在本次提交港股IPO申请前，英矽智能已开展了5轮主要融资。其中，由宜兴市国控集团与锡创投联合 设立的锡创兴宜健康产业基金，于今年初共同领投英矽智能E轮融资，进一步夯实了企业发展基础。在 本次IPO发行中，英矽智能共引入15家顶级投资机构累计认购1.15亿美元，涵盖全球制药企业、互联网 龙头企业、国际主权基金、大型资产管理公司、全球主题基金、国内龙头公募和险资。 围绕宜兴"3+3+N"现代产业集群布局，近年来，宜兴通过构建全链条基金体系和多元化金融工具，系统 性推进基金赋能产业实践。一方面，积极发挥基金引导作用，围绕生物医药、集成电路、低空经济等前 沿产业布局子基金，引导社会资本投向新兴产业领域和高新技术领域。另一方面，用好陶都英才、兴宜 国金等自主管理基金，重点投向创业人才企业、科技创新企业。除此以外，与IDG资本、锡创投等知名 机构合作，吸引社会资本"投早、投小、投长期、投硬科技"，助力宜兴新兴产业快速发展。 英矽智能成立于2014年，是一家业务遍布全球的AI驱动生物科技公司，其商业模式以自研人工智能 Pharma.AI平台为基础 ...

Core Viewpoint - On the penultimate trading day of 2025, the Hong Kong Stock Exchange witnessed a rare listing event with six new companies from various cutting-edge sectors going public, marking the first occurrence of six companies listing simultaneously since July 9 of the same year [1]. Group 1: Company Performances - The leading AI pharmaceutical company, Insilico Medicine, had a remarkable debut, with its stock price opening up by 45.53%, resulting in a profit of 5,475 HKD per lot, as its core Pharma.AI platform significantly reduces drug development cycles to nearly one-fourth of traditional methods [1]. - The digital twin technology company, Wuyi Vision, saw its stock rise by 14.75% at opening, focusing on building a "digital twin earth" and expanding real-time 3D technology applications beyond gaming [1]. - Meilian Holdings and Lin Qingxuan experienced stock increases of 15.63% and 9.3%, respectively, while Xunce and Woan Robotics opened nearly flat, with the former ranking first in the real-time data market for asset management and the latter being the retail sales champion in global home robotics systems [1]. Group 2: Stock Price Movements - Insilico Medicine: 35,000 HKD, +45.53% [2] - Meilian Holdings: 8.210 HKD, +15.63% [2] - Wuyi Vision: 35.000 HKD, +14.75% [2] - Lin Qingxuan: 85.000 HKD, +9.30% [2] - Woan Robotics: 73.800 HKD, 0.00% [2]

Core Viewpoint - InSilico Medicine, a leading AI pharmaceutical company from Yixing, officially listed on the Hong Kong Stock Exchange, marking a significant milestone in its capital market journey and showcasing Yixing's strategic investment in emerging industries [1] Group 1: Company Overview - InSilico Medicine is the 8th company from Yixing to be listed on the Hong Kong Stock Exchange, making Yixing the city with the highest number of listed companies in Wuxi, increasing the total number of listed companies in the city to 20 [3] - The company issued shares at a price of HKD 24.05 per share, planning to issue 94.69 million shares, with an expected fundraising of approximately HKD 2.277 billion, which will be the largest biotech IPO in the Hong Kong market in 2025 [6] Group 2: Use of Proceeds - The funds raised will be used to enhance the AI platform and automate laboratory construction, accelerating the research and development of new molecules, mechanisms, and targets across multiple disease areas, contributing to the digital transformation of the global pharmaceutical industry [6] Group 3: Innovation and Patents - Currently, InSilico Medicine holds 787 patents and patent applications, with over 30 self-developed innovative drug projects, of which 10 have received clinical trial approval [7] - The world's first AI-assisted discovery of a new target and AI-assisted design of an anti-idiopathic pulmonary fibrosis drug, Rentosertib, has completed Phase 2a clinical trials in China with positive results [7] Group 4: Strategic Initiatives - Yixing has consistently focused on company listings as a key strategy to create new engines, reconstruct new dynamics, and enhance new advantages, closely aligning with the city's "3+3+N" modern industrial cluster development [8] - A partnership was established between the municipal state-owned assets group and Xichuang Investment to jointly lead a USD 123 million financing round for InSilico Medicine, creating a platform that integrates "fund + enterprise + project" to drive deep integration of innovation and industry chains [10]

截至最后实际可行日期，公司已通过自主开发的生成式人工智能平台Pharma.AI产生逾20项临床或IND 申报阶段的资产，其中三项资产已授权予国际制药及医疗保健公司，合约总价值最高为21亿美元，以及 一项处于自主开发阶段的II期资产，在业界中处于相对较为先进的阶段。 本文源自：智通财经网 智通财经获悉，英矽智能(03696)首挂上市，公告显示，每股定价24.05港元，共发行9469.05万股股份， 每手500股，所得款项净额约20.26亿港元。截至发稿，涨45.53%，报35港元，成交额3.39亿港元。 公开资料显示，英矽智能是一家全球领先的AI驱动药物发现及开发企业。公司自主研发的生成式人工 智能平台Pharma.AI整合了Biology42、Chemistry42、Medicine42及Science42四大模块，覆盖从新靶点识 别、小分子生成到临床结果预测的端到端药物研发流程。公司通过药物发现及管线开发业务自主开发候 选药物；共同开发授权药物并保留部分知识产权；及与其他制药公司合作但不保留任何知识产权。 ...

当英伟达（NVIDIA）创始人兼CEO黄仁勋在J.P. Morgan医疗健康大会和GTC大会的聚光灯下反复提及这一论断时，生物学正在从一门依赖试错的 实验科学，转变为一门可预测、可编程的数据科学。 而英矽智能（Insilico），正是这个被黄仁勋多次点名的"第一性原理"践行者。 "未来，所有的生物学都将以'计算机模拟'（in silico）为起点，并以'计算机模拟'为很大程度的终点。"（Almost everything will largely start in silico, largely end in silico） 2025年12月30日，英矽智能（3696.HK）在香港联合交易所主板正式挂牌，开盘价报35港元，较发行价升45%，市值达到195亿港元。 | ■ 分时 日 周 月 季 年 1分 5分 15分 30分 60分 多 周 周 安 安 | 竟 九转 则自选 ▼ | | 英矽智能-B 03696 | | 最新 | 35.000 均价 | 38.347 | | --- | --- | --- | --- | --- | --- | --- | --- | | 年67回服-B 分析 15H1: 38 ...

近年来，人工智能(AI)正以惊人的速度从"技术突破"走向"全要素赋能"。尤其在AI制药领域，受益于AI算法和计算能力的深度赋能，生物医药研究达到了前 所未有的速度和精度，由此进入一个高效、个性化和革命性新时代。国际知名咨询公司麦肯锡在此前报告中预测，AI赋能每年有望为制药和医疗行业带来 600-1100亿美元的经济价值。 作为一家拥有独家AI技术平台，还能实现创新药研发及多领域深度赋能的独角兽企业，英矽智能(03696)如今登陆港股，为港股投资者在稀缺的AI赋能投资 赛道带来了一个重磅可选项。 12月30日，英矽智能正式在香港联交所主板挂牌交易。 在全球AI制药赛道更看重平台验证与商业化落地的下半场，作为全球少数实现AI药物发现和开发全流程覆盖的企业之一，英矽智能此次港股IPO能同时得到 豪华基石背书和市场投资者追捧，足以说明当下港股市场已在这家公司上达成了"价值共识"。 相较于随IPO进程逐渐对公司加深价投理解的众多散户投资者，更早之前就站队英矽智能的一众顶级资本，显然更深谙公司的长期价值。 此次IPO发行过程中，英矽智能集聚了包括全球制药巨头礼来公司、互联网龙头企业腾讯、新加坡主权基金淡马锡，以及施罗德、 ...

智通财经APP了解到，英矽智能此次港股IPO备受市场关注。一方面，公司预计募资最高约22.77亿港元，由此成为2025年港市规模最大的生物科技IPO;另一 方面，在此次英矽智能IPO发行过程中，不仅得到了摩根士丹利、中金公司和广发证券的联合保荐，更吸引了包括全球制药巨头礼来、科技巨头腾讯以及橡 树资本、施罗德、淡马锡、瑞银资产等多达15家顶级投资机构的青睐，基石阵容可谓强大。 值得一提的是，按照现行港股通"冲通规则"，英矽智能134.06亿港元的发行市值已高于目前入通门槛，只要在调整考察期结束前2个交易日稳定公司市值与 流动性，公司便有望在明年3月的新一期港股通调整中顺利入通。 近年来，人工智能(AI)正以惊人的速度从"技术突破"走向"全要素赋能"。尤其在AI制药领域，受益于AI算法和计算能力的深度赋能，生物医药研究达到了前 所未有的速度和精度，由此进入一个高效、个性化和革命性新时代。国际知名咨询公司麦肯锡在此前报告中预测，AI赋能每年有望为制药和医疗行业带来 600-1100亿美元的经济价值。 作为一家拥有独家AI技术平台，还能实现创新药研发及多领域深度赋能的独角兽企业，英矽智能(03696)如今登陆港股， ...

Core Viewpoint - Six companies, including Wanan Robotics (6600.HK) and Yingxi Intelligent (3696.HK), successfully listed on the Hong Kong Stock Exchange on December 30, marking the completion of new stock issuances for the year, totaling 117 listings [1]. Group 1: New Listings - The six newly listed companies are Wanan Robotics, Yingxi Intelligent, Xunce, Meilian Holdings, and Linqingxuan [1]. - On their first trading day, only Wanan Robotics opened flat, while the other five stocks experienced gains, with Yingxi Intelligent leading at a 45.53% increase [1]. Group 2: Fundraising Statistics - The total amount raised by the 117 new stocks in Hong Kong for the year is approximately 285.693 billion HKD [1]. - CATL (宁德时代) topped the fundraising list with approximately 41.006 billion HKD, followed by other companies like Zijin Mining International and Sany Heavy Industry, each raising over 10 billion HKD [1].